Data as of Q4 2025 (Dec 31, 2025)

ACORN CAPITAL ADVISORS, LLC

โ€ขCIK: 2054410โ€ขFiling: Q4 2025

**ACORN CAPITAL ADVISORS, LLC** manages $295M across a concentrated portfolio of 21 positions. The fund exhibits significant conviction in its top holdings, led by a substantial allocation to TERN at $70.5M. Further notable positions include CGON at $47.0M and BCLYF at $33.9M, indicating a focused, high-conviction approach. This structure suggests active management targeting specific market opportunities within its current investment universe.

Total AUM
$295.1M
QoQ Performance
+49.8%
Positions
21
Top 10 Concentration
88.7%
Latest Filing
Q4 2025

Top Holdings Allocation

TERN
CGON
UROG
TRVI
PBYI
TERN23.9%
CGON15.9%
UROGEN11.5%
TRVI9.1%
PBYI8.3%
CADL4.9%
HELP4.4%
VSTM3.8%

๐Ÿ“ˆ Biggest Buys

HELP
CYBIN INC
+114.2%
4.4% of portfolio
VSTM
VERASTEM INC
+88.5%
3.8% of portfolio
โ€”
UROGEN PHARMA LTD
+15.0%
11.5% of portfolio
LONA
ATHIRA PHARMA INC.
NEW
1.3% of portfolio
JSPR
JASPER THERAPEUTICS
+29.2%
1.1% of portfolio

๐Ÿ“‰ Biggest Sells

TERN
TERNS PHARMACEUTICALS INC
-11.4%
23.9% of portfolio
QTTB
Q32 BIO INC.
-38.6%
0.6% of portfolio
VYNE
VYNE THERAPEUTICS INC
-99.8%
0.0% of portfolio

Sector Breakdown

Other100.0%

Changes from Q3 2025

NEW1 new position
โ†‘4 increased
โ†“3 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024